On this page
The Cost of Inaction
Before an ROI figure means anything, Finance needs to see the cost of the status quo — the number that makes “we do nothing” a choice with a price tag rather than a free default. At the global level, the World Health Organization estimates that depression and anxiety cost the world economy roughly 12 billion working days every year, and roughly US$1 trillion in lost productivity annually. That is a macro figure, not a per-employer one, but it establishes the scale of the underlying problem your benefit is meant to address.
The employer-level figure that maps more directly onto a Finance memo comes from Gallup, which puts the annual U.S. cost of poor employee mental health at roughly $47.6 billion in lost productivity from unplanned absences alone. The mechanism behind that figure is concrete and worth quoting directly: employees who rate their own mental health as fair or poor miss around 12 unplanned days a year, compared with about 2.5 days for everyone else. That gap — roughly 9.5 extra unplanned absence days per affected employee — is the number to anchor an internal cost-of-inaction estimate to, because it is denominated in something Finance already tracks: absence days, not a soft engagement score.
Framed this way, the business case does not start by asking Finance to believe an AI tool works. It starts by asking Finance to accept a cost that is already being paid, whether or not any benefit exists to address it.
The ROI Figures You Can Actually Defend
The most defensible ROI figure for employer mental-health investment as a category comes from Deloitte Canada’s 2019 analysis, which found a median return of CA$1.62 for every CA$1 invested in employer mental-health programs — a figure that rose to CA$2.18 for programs that had been running for three or more years. Two features of that figure make it worth leading with in a Finance memo: it is a median across a study population rather than a single vendor’s marketing claim, and it shows the return improving with program maturity — a pattern Finance recognizes from every other multi-year investment it evaluates.
You will also see a higher figure circulating: Deloitte UK’s 2024 edition of its own workplace mental-health ROI research reports a considerably larger return per pound invested. Treat that number as directional context only. It is drawn from a literature review of external studies rather than a single tracked program, it is denominated in British pounds against a different cost base, and the figure itself shifts with each new edition of the report. Do not convert the UK figure into your own currency and average it with the Canadian figure — they are not measuring the same thing, and presenting a blended number to Finance manufactures a precision that neither underlying study actually supports. If you cite the UK edition at all, cite it explicitly as “Deloitte UK’s 2024 edition” and use it only to show that the CA$1.62–CA$2.18 range is not an outlier internationally, not as a second number to add to your own projection.
The Honest Caveat: No Workplace Trial Yet
The figure most likely to show up, unattributed, in a vendor deck is some version of “every dollar spent on mental health returns four dollars.” That claim traces back to a WHO-led global modelling study published in The Lancet Psychiatry in 2016. That study modeled the return from scaling up treatment for depression and anxiety across national health systems worldwide — it is not an employer-program ROI study, and it says nothing about any single workplace benefit, digital or otherwise. Presenting it to Finance as “our company will get 4× back” misattributes a population-health modelling exercise as a corporate ROI guarantee, and a sharp Finance partner who looks up the source will notice the mismatch immediately.
Here is the caveat to state plainly, not bury: there is currently no independent, controlled trial of any named AI mental-health chatbot in a workplace population. The ROI case for the category of employer mental-health investment is solid — that is what the Deloitte Canada figure demonstrates. The claim that a specific AI tool, deployed at your company, will deliver that same return is, so far, unproven. Those are two different claims, and a Finance memo that keeps them separate is more credible, not less, than one that blurs them together.
The practical response to that gap is not to abandon the business case — it is to frame the investment as reducing a documented cost of inaction rather than promising a guaranteed multiple, and to start with a pilot that generates your own outcomes data before you scale spend on the strength of a vendor’s unverified figures.
Putting It in a Finance Memo
A defensible memo separates what is documented from what is being tested, in this order:
- The cost of inaction, sourced from WHO and Gallup — the 9.5-day unplanned-absence gap between employees who rate their mental health fair/poor and everyone else is the number to run against your own headcount and average absence cost.
- The category-level return, sourced from Deloitte Canada — CA$1.62 per CA$1 invested, rising to CA$2.18 as the program matures, cited as evidence that employer mental-health investment as a class of spend is well studied and positive.
- The specific-tool caveat, stated in your own words — no independent workplace trial yet exists for any named AI tool, so the memo asks for pilot budget with a measurement plan, not a full rollout budget against a promised multiple.
- The utilization risk, which is where most of the return actually gets lost: a benefit nobody uses returns nothing, no matter how strong its category-level ROI looks on paper. We cover why that gap is so persistent, and what narrows it, in our guide to the benefit most employees never use.
That structure gives Finance something more useful than a single headline number: a chain of reasoning it can interrogate at each link, with the weakest link — tool-specific proof — explicitly flagged rather than smoothed over.
Holding Vendors to Post-Launch Outcomes
Because the tool-specific evidence gap is real, the moment you sign a contract is the start of your evidence base, not the end of your due diligence. Build outcome tracking into the vendor relationship from day one rather than treating it as an afterthought: agree on the utilization and engagement metrics you will collect before launch, set a check-in cadence at defined milestones after go-live, and require the vendor to report against those metrics rather than their own marketing benchmarks. Work through what to ask for — data privacy terms, clinical-evidence claims, crisis-escalation protocols, and what post-launch reporting a contract should actually obligate a vendor to provide — in our vendor RFP checklist.
A pilot, run this way, does double duty: it limits your exposure to the specific-tool evidence gap described above, and it produces the first real data point your own organization can use — something closer to your actual workforce than a global modelling study or a category-wide median ever will be.
Bottom Line
The ROI case for an AI mental-health benefit rests on evidence that is strong in some places and genuinely thin in others, and a credible Finance memo says so. The cost of inaction is well documented — WHO’s 12 billion lost working days globally and Gallup’s $47.6 billion U.S. productivity figure, driven by a roughly 9.5-day unplanned-absence gap, are both citable as-is. The return on employer mental-health investment as a category is also well documented, anchored to Deloitte Canada’s CA$1.62–CA$2.18 range rather than the more headline-grabbing but harder-to-source UK figure or the population-health “4×” claim. What is not yet documented is whether any specific AI tool delivers that category-level return inside a workplace — and the strongest version of your business case names that gap directly, proposes a pilot to close it, and commits to holding the vendor to real post-launch outcomes rather than a promised multiple.
This page is general information for benefits decision-makers, not legal, clinical, or financial advice — confirm the specifics of your own cost base, contract terms, and any vendor claims with your own counsel and financial advisors before you commit budget.
Frequently Asked Questions
What is the most defensible ROI figure for an employee mental-health program?
Deloitte Canada’s 2019 study found a median return of CA$1.62 for every CA$1 invested, rising to CA$2.18 for programs that had been running three or more years. It is a median across a study population rather than a single vendor’s marketing claim, which is why it is the figure we lead with.
Is the “$1 spent returns $4” claim accurate for employers?
No. That figure traces to a WHO-led global modelling study of scaling up depression and anxiety treatment worldwide — not an employer-program ROI. It should not be presented as a return your own company will get.
Can I promise Finance a specific return from an AI mental-health tool?
Not honestly. There is no independent, controlled trial of any named AI mental-health chatbot in a workplace population, so the return for any specific tool is unproven. Frame the case as reducing a documented cost of inaction, and hold the vendor to outcomes reporting after launch.
What figures show the cost of inaction?
The WHO estimates that 12 billion working days are lost every year to depression and anxiety, and Gallup puts the cost of poor employee mental health at about $47.6 billion a year in US productivity losses from unplanned absences.
Related Reading
- AI Mental Health Tools for Employee Benefits: An HR Buyer’s Guide — the fuller buyer’s guide this ROI case sits inside
- Employee Mental-Health Benefit Utilization — why the strongest ROI figure means little if utilization stays low
- Running an AI Mental-Health Benefit Pilot — how to structure the pilot this ROI case argues for
- AI Mental-Health Vendor RFP Checklist — what to require in the contract, including post-launch outcomes reporting